TOP HEADLINES

Featured Story

'Safe' social network LinkedIn emerges as popular marketing tool for pharma

LinkedIn's professional social network appeals to business people, networkers and recruiters, but also to industries that tend to be more cautious on social media. Welcome, pharma. "Healthcare, overall, and pharma is definitely on the developmental side of the LinkedIn spectrum, if you will, from an advertising perspective," said Stephanie Katzman, LinkedIn's healthcare lead in its Marketing Solutions group. "But over the past three years, we've seen a huge growth in having these companies consider LinkedIn as a channel."

GSK's slow-off-the-blocks Anoro gets a leg up from Incruse sidekick

Not every market has been enthusiastic about slow-starting GlaxoSmithKline respiratory newcomer Anoro. But the company has been offering doctors another option, too--and it's starting to pay off.

Omega diet-aid ad banned in U.K.; summer slimming promos not 'socially responsible'

Omega Pharma's advertising for its diet pill XLS Medical found itself in the middle of a dust-up in Britain, with hundreds of complaints flying about the swimsuit-season promos. And now, the campaign is banned altogether.

Docs take aim at Novartis' 'horrifying' Entresto ad

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.

BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa

Bristol-Myers Squibb and Pfizer's next-gen anticoagulant, Eliquis, may have rolled out at a snail's pace. But these days, the drug is topping Bristol-Myers' sales charts--and the company believes it will top the other drugs in its class before long.

MORE NEWS